



September 29, 2022
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Establishment of JCR Europe as Overseas Subsidiary to Become a Base for Development in Europe

September 29, 2022 – JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced that effective September 15, 2022, it established JCR Europe B.V. (“JCR Europe”) as new subsidiary, serving primarily as a base for conducting clinical development activities in Europe. JCR Europe will be headquartered in Leiden, the Netherlands. Anne Bechet has been appointed as the General Manager of JCR Europe. The establishment of JCR Europe comes as a natural extension of JCR’s aim to be a research-oriented specialty pharma with global exposure.

JCR established JCR Europe in the Netherlands to strengthen clinical operations, regulatory affairs and development capabilities in Europe. Building such capacities in Europe will allow JCR to flexibly allocate resources to clinical trials globally and to be in proximity to sites where clinical trials are conducted. JCR Europe will interact seamlessly with the development organizations in Japan, the United States and Brazil. In addition, JCR Europe will further enhance its network with clinicians, patient advocacy groups, regulatory bodies and other key stakeholders in the field of rare diseases. The establishment of JCR Europe is a testament of JCR Pharmaceutical’s ongoing commitment as a specialty pharma to continue to contribute to treatment of patients with rare diseases throughout the world.

JCR has built an industry-leading portfolio of lysosomal storage disease (LSD) assets that are all based on the J-Brain Cargo® technology which allows enzyme-replacement therapies to cross the blood-brain-barrier and to treat the CNS sequelae of LSDs in addition of the somatic signs and symptoms of these diseases. Several programs are already in advanced clinical trials or will enter clinical development soon. Among these are JR-141 (INN: pabinafusp alfa) for the treatment of mucopolysaccharidosis (MPS) type II; JR-171 (INN: lepunafusp alfa) for the treatment of MPS type I; JR-441 for the treatment of MPS type III-A (Sanfilippo syndrome type A); JR-446 for the treatment of MPS type III-B (Sanfilippo syndrome type B); JR-479 for the treatment of GM2 gangliosidosis (Tay-Sachs disease, Sandhoff disease), and others.

This matter has been factored into JCR’s consolidated financial results for the year ending March 31, 2023.

< Overview of Subsidiary Company >

(1) Corporate name	JCR Europe B.V.
(2) Location	Leiden, the Netherlands
(3) Representative	Anne Bechet, General Manager
(4) Business	<ul style="list-style-type: none">· Clinical operations regulatory and development in Europe· Enhance the network with clinicians, patient advocacy groups, regulatory bodies and other key stakeholders in the field of rare diseases in Europe· Business development
(5) Working capital	€500K WC (Approximately 70 million yen)
(6) Date of establishment	September 15, 2022
(7) Fiscal Year-end	31, December
(8) Investment ratio	JCR Pharmaceuticals Co., Ltd. 100%

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 48-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), MPS III A and B (Sanfilippo syndrome type A and B) disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jcrpharm.co.jp

###